Cardiovascular Patient Articles & Analysis
32 news found
The study demonstrated that finerenone reduced the risk of cardiovascular events in a broad population of patients with stages 1-4 CKD and T2D. ...
ByBayer AG
Abstract Project Summary Abstract The epidemic of cardiovascular diseaseCVDis a global phenomenon that remains the number one cause of death throughout the worldkilling nearlymillion people per yeara number that is expected to grow tomillion byA high cholesterol level is well known risk factors for heart diseaseAlthough blood cholesterol can be lowered using a number of ...
” The product labels of all JAK inhibitors will be updated to include a precautionary approach for patients aged 65 years or above, those at increased risk of major cardiovascular problems (such as heart attack or stroke), those who smoke or have done so for a long time in the past and those at increased risk of cancer. ...
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke events in patients with atrial fibrillation as well as patients with a non-cardioembolic ischemic stroke or high-risk transient ischemic attack involving up to 30,000 patients Bayer drives the development of its ...
ByBayer AG
The chief technician of BOC Sciences expatiates some information about C-peptide as an example, "Our C-peptide can alleviate and delay the occurrence and development of chronic complications such as kidney, nerve, and cardiovascular in patients with type 1 diabetes by activating some enzymes, which provides a new solution to the treatment of type 1 diabetes." ...
“As a thought leader in cardiovascular medicine and a foremost expert in CT angiography, his extensive experience in cardiovascular disease assessment will be an invaluable asset for Elucid and his contributions will substantially impact patient care globally. ...
ByElucid
“Elucid is committed to providing physicians the most rigorously validated diagnostic platform to fight cardiovascular disease. Every patient is different and needs to be treated specific to his or her individual disease,” said Blake Richards, Chief Executive Officer of Elucid. ...
ByElucid
Cardiac CT combined with SQuEEZ analysis software can provide clinicians with a normalized measurement to determine the answer to the first and most important clinical question a cardiac surgeon needs to know for patients with Cardiovascular Disease (CVD) symptoms— “Is the contractile function normal or not normal?” SQuEEZ allows the surgeon to ...
Thoma Bravo, a leading software investment firm, today announced the completion of its strategic growth investment in Circle Cardiovascular Imaging Inc. ("Circle CVI"), the global leader in cardiovascular imaging solutions. ...
We are happy to add this outcomes study to the growing body of evidence supporting the broad application of FFRangio in the intraprocedural assessment of patients with coronary artery disease,” said Dr. Witberg. “CathWorks is grateful for the partnership with the study investigators as we continue to broaden the global clinical adoption of FFRangio and work towards ...
Despite well-controlled blood glucose levels and blood pressure, patients with chronic kidney disease and type 2 diabetes remain at risk of chronic kidney disease progression and cardiovascular death,” said Dr. ...
ByBayer AG
Circle Cardiovascular Imaging Inc. ("Circle CVI"), the global leader in cardiovascular imaging solutions, today announced a strategic growth investment from Thoma Bravo, a leading software investment firm. ...
“We are encouraged by the long-term follow-up of these patients and look forward to longer term outcomes from the ongoing Revitalize T2D clinical development program in patients across the spectrum of ...
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces the appointment of Professor Daniel Wendt, MD, PhD, MHBA, FETCS as Vice President, Medical Affairs Cardiovascular commencing January 1, 2022. Dr. Wendt is an internationally renowned academic cardiac ...
In these studies, finerenone demonstrated benefits on kidney and cardiovascular outcomes in patients with CKD and T2D. Finerenone demonstrated a consistent safety profile across studies. ...
ByBayer AG
The STAR-T trial is expected to enroll up to 120 patients across 20 sites and be completed by 2022. The first patient was enrolled by Dr. ...
CathWorks, a global leader of digital health innovation focused on helping patients with cardiovascular disease, announced today that Mike Feher was appointed Chief Financial Officer, effective immediately. ...
In a pilot study of 24 pediatric patients requiring postcardiotomy extracorporeal membrane oxygenation (ECMO) for severe refractory cardiogenic shock after ischemia reperfusion injury, 10 were treated with intramyocardial autologous mitochondrial transplantation. ...
Hanover, Germany, June 24, 2021 - Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) based therapeutics for patients with cardiovascular diseases, announced today that results from a recent peer-reviewed study underlining the Company´s pioneering approach in the treatment of cardiac diseases ...
CathWorks , a global leader of digital health innovation focused on helping patients with cardiovascular disease, today announced that Ramin Mousavi has been appointed Chief Executive Officer, effective June 21, 2021. ...